US FDA extends review of Travere’s drug for rare kidney disease

Travere Therapeutics

13/01/2026 18:27

Jan 13 (Reuters) - The U.S. Food and Drug Administration has extended its review for the expanded use of Travere Therapeutics’TVTX.O drug to treat a type of rare kidney disorder, the drugmaker said on Tuesday.

The agency will now give its decision on April 13, compared to its previous action date of January 13.

 (Reporting by Sahil Pandey and Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)

 ((Sahil.Pandey@thomsonreuters.com;))